GlassScriptPhysician profile
Salman Majeed
NPI 1750659520
$1,436.94
in general payments reported to CMS, 2019-2025
11 companies · $658 in 2025
The $658 reported for 2025 was more than what 80% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $222 · 2020: $210 · 2023: $94.86 · 2024: $253 · 2025: $658.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $677 · Travel and Lodging: $273 · Education: $54.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $677.41 |
| Travel and Lodging | $273.00 |
| Education | $54.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $692.23 | 2020-2025 | Spravato |
| Astrazeneca Pharmaceuticals LP | $216.43 | 2019-2024 | Lokelma |
| Sunovion Pharmaceuticals INC. | $148.76 | 2019-2020 | |
| Nevro Corp. | $143.77 | 2020 | |
| Harmony Biosciences LLC | $68.69 | 2025 | |
| Neuronetics, INC. | $38.38 | 2019-2023 | Neurostar Tms Therapy System |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $38.11 | 2023-2025 | Caplyta |
| Alkermes, INC. | $28.09 | 2019-2020 | |
| Axsome Therapeutics, INC. | $27.56 | 2024-2025 | Auvelity |
| Lundbeck LLC | $22.18 | 2024 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $12.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salman Majeed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.